Skip to main navigation Skip to search Skip to main content

Bxq-350 in combination with FOLFOX7 and bevacizumab: Evaluation of effect on oxaliplatin-induced CIPN—A phase 1b/2 trial to assess the efficacy and safety of BXQ-350, a first-in-class sphingolipid metabolism modulator, in newly diagnosed metastatic colorectal carcinoma.

  • Tariq Arshad
  • , Michael Gazda
  • , Gilles Tapolsky
  • , Jim Beach
  • , Daniel Blake Flora
  • , Reema Anil Patel
  • , Fa Chyi Lee
  • , Douglas B. Flora
  • , Davendra Sohal
  • , Saima Sharif
  • , Ki Young Chung
  • , John L. Villano
  • , Vivek Sharma
  • , Julie Anne L. Gemmill
  • , Agustin Pimentel
  • , Nashat Y. Gabrail
  • , Darryl Alan Outlaw
  • , Ari David Baron
  • , Brian C. Boulmay
  • Bexion Pharmaceuticals
  • St. Elizabeth Medical Center, Edgewood
  • University of Kentucky
  • University of California at Irvine
  • Inc
  • University of Cincinnati
  • University of Iowa
  • Institute for Translational Oncology Research
  • James Graham Brown Cancer Center
  • University of Miami
  • Gabrail Cancer and Research Center
  • University of Alabama at Birmingham
  • Pacific Hematology Oncology Associates
  • Louisiana State University Health New Orleans

Research output: Contribution to journal › Review article › peer-review

Abstract

105Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a significant side effect associated with many cancer drugs and is highly prevalent in mCRC patients receiving oxaliplatin-based regimens. CIPN can severely impact quality of life (QoL) and may require dose vacation, reduction or interruption. CIPN pathology is complex and not completely understood; preclinical and clinical data have shown inflammatory (IL-6, Il-8, IL-10) and immune involvement as well as elevated levels of sphingolipids, a class of bioactive signaling molecules. BXQ-350 is a nanovesicle formulation of Saposin C, an allosteric activator of sphingolipid metabolism that normalizes dysregulated sphingolipid metabolism by lowering S1P, GM3 and GluCer levels while it increases ceramide level, promoting a return to homeostasis. In a single agent Phase 1 study, BXQ-350 was safe and well-tolerated and showed signs of activity. Among patients with PFS > 6 months, there were 4 recurrent CRC patients: 1 is still on study after 7 years. One patient self-reported an improvement of their pre-existing CIPN symptoms after BXQ-350 administration; this observation was confirmed in 4 of 10 patients with established CIPN at the time of enrollment. Methods: BXQ-350 is being investigated in a Phase 1b/2 study in combination with mFOLFOX7 and Bevacizumab (SoC) in newly diagnosed mCRC patients (NCT05322590). Primary objectives are to assess safety and preliminary efficacy of this combination, and to determine cumulative oxaliplatin dose. Secondary objectives include intensity, frequency and time to onset of CIPN. Results: The Phase Ib trial enrolled 33 oxaliplatin dosing evaluable patients; all patients completed the primary treatment period (6 months of SoC treatment plus BXQ-350). Amongst the 33 patients, 19 completed the full 12 Cycles of oxaliplatin dosing, 28 completed at least 8 Cycles with only 2 patients having dosing halted before Cycle 8 due to CIPN. There were no reported Grade 4 and only 3 reported Grade 3 CIPN AEs, all occurred after Cycle 12. Analysis of Neurofibrillary Light Chain (NfL) biomarkers suggests concordance with physician and patient reported outcomes. Conclusions: Results show that BXQ-350 was safe and well tolerated in the combination. Data suggest that BXQ-350 may provide additional clinical benefits and may reduce intensity or delay onset of CIPN, allowing for increased cumulative dosing of oxaliplatin and relative dose intensity in 1L mCRC. Clinical trial information: NCT05322590.

Original languageEnglish
Pages (from-to)105
Number of pages1
JournalJournal of Clinical Oncology
Volume44
DOIs
StatePublished - Jan 2026

Fingerprint

Dive into the research topics of 'Bxq-350 in combination with FOLFOX7 and bevacizumab: Evaluation of effect on oxaliplatin-induced CIPN—A phase 1b/2 trial to assess the efficacy and safety of BXQ-350, a first-in-class sphingolipid metabolism modulator, in newly diagnosed metastatic colorectal carcinoma.'. Together they form a unique fingerprint.

Cite this